Breakthrough in Treatment for Rare Blood Vessel Disorder

Researchers at the Cleveland Clinic have discovered that the cancer drug pomalidomide effectively treats hereditary hemorrhagic telangiectasia (HHT), a rare bleeding disorder, SciTech Daily reported on Wednesday.

In a clinical trial led by Dr. Keith McCrae, the study was halted early due to promising results, showing significant reductions in nosebleed severity and improved quality of life for participants.

Enrolling 144 adults across 11 medical centers, the trial found that patients required fewer blood transfusions. Pomalidomide, an FDA-approved medication for bone marrow cancer, offers hope for long-term management of HHT, which currently has no approved treatments. Further research is planned to explore the drug’s mechanisms and potential as a long-term solution.